Advanced

Increased serum type I interferon activity in early systemic sclerosis patients is associated with antibodies against Sjögren's syndrome antigens and nuclear ribonucleoprotein antigens.

Wuttge, Dirk LU ; Lood, Christian LU ; Tufvesson, Ellen LU ; Scheja, Agneta LU ; Truedsson, Lennart LU ; Bengtsson, Anders LU and Hesselstrand, Roger LU (2013) In Scandinavian Journal of Rheumatology 42(3). p.235-240
Abstract
Objective: To study serum type I interferon (IFN) activity in patients with early systemic sclerosis (SSc). Method: Serum type I IFN activity was measured in 33 consecutive patients with SSc and a disease duration of < 2 years and in 13 healthy individuals by calculating a type I IFN score according to the induction of six IFN-α regulated genes in a reporter cell line. Results: Twenty-seven per cent of the SSc patients had an increased type I IFN score compared to none of the healthy individuals (p < 0.05). The clinical SSc phenotype associated with high serum type I IFN activity did not differ from patients with low serum type I IFN activity regarding the presence of skin or lung fibrosis, pulmonary hypertension, or digital... (More)
Objective: To study serum type I interferon (IFN) activity in patients with early systemic sclerosis (SSc). Method: Serum type I IFN activity was measured in 33 consecutive patients with SSc and a disease duration of < 2 years and in 13 healthy individuals by calculating a type I IFN score according to the induction of six IFN-α regulated genes in a reporter cell line. Results: Twenty-seven per cent of the SSc patients had an increased type I IFN score compared to none of the healthy individuals (p < 0.05). The clinical SSc phenotype associated with high serum type I IFN activity did not differ from patients with low serum type I IFN activity regarding the presence of skin or lung fibrosis, pulmonary hypertension, or digital complications. Patients with high serum type I IFN activity were younger (p < 0.01) and had a lower frequency of cardiac involvement (p = 0.053), lower leucocyte count (p < 0.001), higher immunoglobulin (Ig)G levels (p < 0.05), and a higher amount of antibodies against extractable nuclear antigens (p < 0.01) than patients with low serum type I IFN activity. The presence of antibodies against topoisomerase I, Sjögren's syndrome antigen, and nuclear ribonucleoprotein antigens was associated with higher type I IFN activity (p < 0.05 for all comparisons). Conclusions: Our study indicates that increased serum type I IFN activity in early SSc patients is associated with an antibody and laboratory profile that may reflect a subclinical overlap of SSc with other type I IFN-driven connective tissue diseases (CTDs). (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Scandinavian Journal of Rheumatology
volume
42
issue
3
pages
235 - 240
publisher
Taylor & Francis
external identifiers
  • wos:000319036800013
  • pmid:23379597
  • scopus:84877884719
  • pmid:23379597
ISSN
1502-7732
DOI
10.3109/03009742.2012.736532
language
English
LU publication?
yes
id
f23020d5-2d2e-4fef-97ee-71c4ad0d8ab9 (old id 3560236)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/23379597?dopt=Abstract
date added to LUP
2016-04-01 10:28:08
date last changed
2020-01-12 03:51:41
@article{f23020d5-2d2e-4fef-97ee-71c4ad0d8ab9,
  abstract     = {Objective: To study serum type I interferon (IFN) activity in patients with early systemic sclerosis (SSc). Method: Serum type I IFN activity was measured in 33 consecutive patients with SSc and a disease duration of &lt; 2 years and in 13 healthy individuals by calculating a type I IFN score according to the induction of six IFN-α regulated genes in a reporter cell line. Results: Twenty-seven per cent of the SSc patients had an increased type I IFN score compared to none of the healthy individuals (p &lt; 0.05). The clinical SSc phenotype associated with high serum type I IFN activity did not differ from patients with low serum type I IFN activity regarding the presence of skin or lung fibrosis, pulmonary hypertension, or digital complications. Patients with high serum type I IFN activity were younger (p &lt; 0.01) and had a lower frequency of cardiac involvement (p = 0.053), lower leucocyte count (p &lt; 0.001), higher immunoglobulin (Ig)G levels (p &lt; 0.05), and a higher amount of antibodies against extractable nuclear antigens (p &lt; 0.01) than patients with low serum type I IFN activity. The presence of antibodies against topoisomerase I, Sjögren's syndrome antigen, and nuclear ribonucleoprotein antigens was associated with higher type I IFN activity (p &lt; 0.05 for all comparisons). Conclusions: Our study indicates that increased serum type I IFN activity in early SSc patients is associated with an antibody and laboratory profile that may reflect a subclinical overlap of SSc with other type I IFN-driven connective tissue diseases (CTDs).},
  author       = {Wuttge, Dirk and Lood, Christian and Tufvesson, Ellen and Scheja, Agneta and Truedsson, Lennart and Bengtsson, Anders and Hesselstrand, Roger},
  issn         = {1502-7732},
  language     = {eng},
  number       = {3},
  pages        = {235--240},
  publisher    = {Taylor & Francis},
  series       = {Scandinavian Journal of Rheumatology},
  title        = {Increased serum type I interferon activity in early systemic sclerosis patients is associated with antibodies against Sjögren's syndrome antigens and nuclear ribonucleoprotein antigens.},
  url          = {http://dx.doi.org/10.3109/03009742.2012.736532},
  doi          = {10.3109/03009742.2012.736532},
  volume       = {42},
  year         = {2013},
}